LOGIN  |  REGISTER

List of Big Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 574.59
26.21 4.78
2.49M
381.71M
US$ 219.330B
US$ 253.11
17.03 7.21
6.52M
740.54M
US$ 187.440B
US$ 107.59
0.52 0.49
3.63M
1.74B
US$ 187.210B
US$ 377.08
8.15 2.21
1.84M
354.71M
US$ 133.750B
US$ 334.91
7.23 2.21
1.33M
380.47M
US$ 127.420B
US$ 81.29
0.72 0.89
5.04M
1.33B
US$ 108.120B
US$ 68.99
0.97 1.43
8.91M
1.47B
US$ 101.420B
US$ 234.36
0.48 0.21
800,504
288.90M
US$ 67.710B
US$ 87.75
0.79 0.91
2.56M
601.93M
US$ 52.820B
US$ 134.00
2.48 1.89
2.01M
385.52M
US$ 51.660B
US$ 238.62
7.28 3.15
1.07M
182.01M
US$ 43.430B
US$ 139.20
5.29 3.95
1.94M
293.06M
US$ 40.790B
US$ 80.76
0.15 0.19
940,672
493.24M
US$ 39.830B
US$ 390.20
14.85 3.96
419,546
73.21M
US$ 28.570B
US$ 184.22
3.87 2.15
1.11M
147.09M
US$ 27.100B
US$ 1.00
41.86 3.49
113,533
21.39M
US$ 26.550B
US$ 306.45
8.52 2.86
797,872
82.50M
US$ 25.280B
US$ 103.37
0.54 0.53
2.38M
243.23M
US$ 25.140B
US$ 121.51
0.72 0.60
680,984
205.46M
US$ 24.960B
US$ 41.02
0.62 1.53
2.55M
509.35M
US$ 20.890B
US$ 205.99
5.09 2.53
542,528
98.81M
US$ 20.350B
US$ 124.46
4.21 3.50
1.30M
159.26M
US$ 19.820B
US$ 207.97
4.90 2.41
888,805
84.13M
US$ 17.500B

Latest Big Medical Stocks News


Thermo Fisher Scientific Reports First Quarter 2024 Results

WALTHAM, Mass. / Apr 24, 2024 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Highlights First quarter revenue was $10.34 billion. First quarter GAAP diluted earnings per share (EPS) increased 4% to $3.46. First quarter adjusted EPS increased 2% to $5.11. Advanced our proven growth strategy, launching a range... Read more


Danaher Reports First Quarter 2024 Results

WASHINGTON, April 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 29, 2024.  All results in this release reflect only continuing operations unless otherwise noted. Key First Quarter 2024 Results Net earnings were $1.1 billion, or $1.45 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.92. Revenues decreased 2.5% year-over-year to $5.8 billion... Read more


Intuitive Surgical Announces First Quarter Earnings

SUNNYVALE, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2024. Q1 Highlights Worldwide da Vinci procedures grew approximately 16% compared with the first quarter of 2023. The Company placed 313 da Vinci surgical systems, compared with 312 in the first quarter... Read more


Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges

Sales of $10.0 billion driven by strong underlying base business performance Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior year Organic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth1 ABBOTT PARK, Ill., April 17, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for... Read more


Agilent Technologies Receives European IVDR Class C Certification for GenetiSure Dx Postnatal Assay

SANTA CLARA, Calif. / Apr 15, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification. This certification demonstrates that the assay meets the higher standards established by IVDR. It ensures the continued availability of this trusted qualitative assay to clinical geneticists and other healthcare professionals throughout the EU. In vitro diagnostic devices, which include... Read more


Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Innovative GFAP blood biomarker test expands Labcorp's portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C., April 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (GFAP), a critical blood-based biomarker for the early detection... Read more


Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

Five new launches reinforce Baxter’s focus on differentiated products and enhance the company’s Pharmaceuticals portfolio in critical therapeutic areas Products feature ready-to-use formulations to help support patient safety and offer added convenience for healthcare professionals DEERFIELD, Ill. / Apr 11, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, announced the continued expansion... Read more


Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit

The first at-home mpox testing kit provides patients with convenience and privacy to test for mpox, supports physicians in detection and treatment BURLINGTON, N.C., April 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Mpox  PCR Test Home Collection Kit to aid in the diagnosis of... Read more


Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments. Ankur Dhingra is joining... Read more


IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud

RESEARCH TRIANGLE PARK, N.C. & SAN FRANCISCO, CA / Apr 08, 2024 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life sciences industry. Building on the... Read more


The Medtronic Sphere-360™ Pulse Field Ablation (PFA) catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation

EHRA late-breaking data: Results highlight efficacy, safety, and durability of the novel PFA catheter that is fully integrated with Affera™ Mapping and Ablation System DUBLIN and BERLIN, April 8, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for Sphere-360™, an investigational single-shot mapping and ablation catheter using pulsed field (PF)... Read more


Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module

MARLBOROUGH, Mass., April 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation (PFA) Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation (AF). The FARAVIEW technology and the FARAWAVE Nav catheter expand the capabilities of the FARAPULSE™ PFA System through integration... Read more


Medtronic: SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN and ATLANTA, April 7, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), were presented as a late... Read more


Medtronic: New survey uncovers lack of awareness around heart valve disease and risk factors among women

Despite prevalence of chronic conditions associated with aortic stenosis in women over 65, the majority have never been referred to a cardiologist; Racial disparities may present further opportunities for awareness amongst women at risk for cardiovascular disease   DUBLIN, April 7, 2024 /CNW/ -- Medtronic plc, a global leader in healthcare technology, today unveiled topline findings of its comprehensive survey on women's perceptions and knowledge of risk factors,... Read more


Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research

Labcorp Plasma Detect is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer BURLINGTON, N.C., April 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular residual disease (MRD) solution... Read more


Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery More than 1.6 million people in the U.S. are affected by tricuspid regurgitation,1 which can severely impact quality of life Data from the TRILUMINATE™ Pivotal trial demonstrated that patients who received TriClip experienced a marked improvement in the severity of their symptoms and quality of life, with benefits... Read more


Cardinal Health announces location of pharmaceutical distribution center for over-the-counter products

The Consumer Health Logistics Center will be located in Central Ohio and serve as a centralized hub for distribution of consumer health products COLUMBUS, Ohio, April 2, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) announced that construction has begun for a new 350,000 square-foot logistics center in Columbus, Ohio, that will serve as a centralized replenishment center for the distribution of over-the-counter consumer health products in support of... Read more


Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), or concussion The test produces lab-quality results in 15 minutes Clinicians are now able to get a result at the patient's bedside, making the test accessible at urgent care clinics and other healthcare settings outside the hospital emergency room The test can be used to help evaluate patients up to 24 hours... Read more


Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration With Labcorp

Longstanding partnership deepens with new financing, beta access to clinical manufacturing instruments, and AACR data presentations SAN FRANCISCO / Apr 01, 2024 / Business Wire / Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced it has added new elements to its research collaboration agreement with Labcorp, a global leader of innovative and comprehensive laboratory services. Through the expanded... Read more


Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy

Novum IQ Infusion Platform now offers large volume and syringe infusion smart pumps on an integrated system with shared innovative digital health solutions to help enhance patient safety and efficiency for clinicians Common user interface and connectivity across both pump modalities are designed to help reduce workflow burden and allow more time focused on patient care DEERFIELD, Ill. / Apr 01, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), an innovative... Read more


Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

The Evolut™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access DUBLIN, March 27, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut... Read more


Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care  BURLINGTON, N.C., March 20, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and immediate availability of its test to identify the presence or absence of phosphorylated tau 217 (pTau217), a pivotal blood biomarker designed to aid in the... Read more


Canadian First - Abbott Advances Chronic Pain Management with the World's Smallest Implanted, Rechargeable Spinal Cord Stimulation System

Abbott's Eterna™ SCS system to treat chronic pain was used for the first time in Canada at Hôpital de l'Enfant-Jésus hospital in Quebec City.The device is the smallest implantable rechargeable spinal cord stimulator (SCS)*3 and provides the ability to deliver therapy while only requiring wireless recharging five times per year,1,2 meaning less frequent charging for the chronic pain patients being treated.§4MONTRÉAL, March 19, 2024 /CNW/ -- Abbott... Read more


Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with... Read more


Intuitive Surgical Announces FDA Clearance of Fifth-Generation Robotic System, da Vinci 5

SUNNYVALE, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) provided 510(k) clearance for da Vinci 5, the company’s next-generation multiport robotic system. “We are pleased to receive FDA clearance for our fifth-generation robotic system, da Vinci 5,” said Gary Guthart, CEO. “Intuitive... Read more


Becton Dickinson: New Study Highlights Benefits of Medication Management Automation in Long-Term Care Facilities

Results Show Clinical Workflow, Operational Efficiency and Financial Improvements When Using Automated Dispensing Cabinets  FRANKLIN LAKES, N.J., March 13, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data from a research study evaluating the impact of deploying automated dispensing cabinets in long-term care facilities and an off-site, long-term care pharmacy.... Read more


Edwards Lifesciences: Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

WASHINGTON / Mar 11, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform. A study of Edwards’ latest TAVR technology, the SAPIEN 3 Ultra RESILIA valve, found lower rates of paravalvular leak (PVL) at 30 days, lower... Read more


New real-world data shows MiniMed™ 780G system sustains strong global performance, exceeding international targets for diabetes management

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures DUBLIN and FLORENCE, Italy, March 9, 2024 /PRNewswire/ -- Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data from early users in the United States.... Read more


Labcorp Launches Weight Loss Management Testing Solutions

New offering to support individuals and physicians with accessible and convenient testing options to guide weight loss management decisions and treatments BURLINGTON, N.C., March 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the introduction of its Weight Loss Management portfolio. The new offering features educational resources and convenient testing solutions, equipping individuals... Read more


Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask

Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask. Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night. 96% of patients using the AirFit F40 said they have the freedom to sleep in their preferred position and change positions... Read more


Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results were achieved irrespective of GLP-1 duration, GLP-1 type, or insulin therapy type FreeStyle Libre systems help people adhere to diabetes treatment plans and support positive behavior changes by providing real-time data that shows how food, activity and medication can impact... Read more


Alcon: Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

Vivity is the most implanted extended depth of focus (EDOF) intraocular lens (IOL) globally1 Milestone underscores the impact of Vivity’s first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients2,3 Vivity demonstrates excellent outcomes, with real-world Vivity Registry data from more than 900 cataract patients, including patients with certain mild comorbidities as well as post-refractive eyes4 FORT... Read more


Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter

Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor worn on the back of the upper arm, Stelo will provide glucose insights directly to a user’s smartphone† Created by the makers of Dexcom G7, the most accurate,1 easy-to-use2 and clinically-proven CGM brand,3-7 Stelo will empower even more people with Type 2 diabetes not... Read more


Becton Dickinson Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

First Patient Enrollment in AGILITY Study Begins Investigations of Safety and Effectiveness of BD Vascular Covered Stent for Treatment of PAD FRANKLIN LAKES, N.J., March 4, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in the investigational device exemption (IDE) study, "AGILITY," which will assess the safety and effectiveness of the BD Vascular... Read more


Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon

First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.... Read more


Bob Azelby to join Cardinal Health Board of Directors

DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Mr. Azelby has previously served as President... Read more


Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023

Q4 2023 sales of $2.3 billion, up 8%, or 10% constant currency(1) (cc) Q4 2023 diluted EPS of $0.86, compared to a loss in the prior year(3); core diluted EPS(2) of $0.70 up 67%, or 78% cc FY 2023 sales of $9.4 billion, up 8%, or 10% cc FY 2023 diluted EPS of $1.96, up 188%; core diluted EPS of $2.74, up 22%, or 33% cc FY 2024 outlook: 6% to 8% cc sales growth, 13% to 16% cc core diluted EPS growth Ad Hoc Announcement Pursuant to Art. 53 LR GENEVA / Feb 27, 2024... Read more


Agilent Technologies Reports First-Quarter Fiscal Year 2024 Financial Results

Revenue and earnings exceed Q1 guidance Full-year outlook maintained Highlights Revenue of $1.66 billion, down 5.6% reported and 6.4% core(1) from the first quarter of 2023. GAAP net income of $348 million; earnings per share (EPS) of $1.18, down 1% from the first quarter of 2023. Non-GAAP(2) net income of $380 million; EPS of $1.29, down 6% from the first quarter of 2023. Full-year revenue outlook maintained at $6.710 billion to $6.810 billion, representing a... Read more


ICON to Present at Upcoming Investor Conferences

DUBLIN / Feb 26, 2024 / Business Wire / ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024 at 11:10 am ET and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 2:05 pm ET. Any changes... Read more


ICON Reports Fourth Quarter and Full Year 2023 Results

Highlights Net business wins in the quarter of $2,531 million; a net book to bill of 1.22. Full year net business wins of $9,946 million; a net book to bill of 1.22. Closing backlog of $22.8 billion, an increase of 2.4% on quarter three 2023 and an increase of 10.0% on quarter four 2022. Quarter four revenue of $2,066.2 million representing an increase of 5.3% on prior year revenue. Full year revenue of $8,120.2 million representing a year on year increase of 4.9%. Quarter... Read more


Becton Dickinson Partners with Camtech Health to Increase Access to Cervical Cancer Screening in Singapore

First-Ever Program in the Country to Offer At-Home Self-Collection of Samples for HPV Testing SINGAPORE, Feb. 21, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample in... Read more


Medtronic reports third quarter fiscal 2024 financial results

Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S. business returns to growth; Raises full year guidance DUBLIN, Feb. 20, 2024 /CNW/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024. Key Highlights Revenue of $8.1 billion increased... Read more


Labcorp Announces 2023 Fourth Quarter and Full Year Results

Company Provides 2024 Guidance Results from Continuing Operations for the fourth quarter and full year versus last year: Revenue: Q4 of $3.03 billion vs $2.93 billion; Full year of $12.16 billion vs $11.86 billion Diluted EPS: Q4 of $(1.95) vs $0.42 ; Full year of $4.33 vs $10.94 Adjusted EPS: Q4 of $3.30 vs $3.05 ; Full year of $13.56 vs $16.66 Free Cash Flow: Q4 of $414.2 million vs $508.1 million; Full year of $748.7 million vs $1.34 billion Announced six... Read more


West Pharmaceutical Announces Fourth-Quarter and Full-Year 2023 Results

Conference Call Scheduled for 9 a.m. EST Today  EXTON, Pa., Feb. 15, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2023 and introduced full-year 2024 financial guidance. Fourth-Quarter and Full-Year 2023 Summary (comparisons to prior-year period) Fourth-quarter 2023 net sales of $732.0 million grew 3.3%; organic net sales growth was 1.4%. Full-year 2023 net sales... Read more


IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance

Revenue of $3,868 million for the fourth quarter, $14,984 million for the full year GAAP Net Income of $469 million for the fourth quarter, $1,358 million for the full year Adjusted EBITDA of $966 million for the fourth quarter, $3,569 million for the full year GAAP Diluted Earnings per Share of $2.54 for the fourth quarter, $7.29 for the full year Adjusted Diluted Earnings per Share of $2.84 for the fourth quarter, $10.20 for the full year R&D Solutions quarterly... Read more


FDA Advisory Committee Votes in Favor of Abbott's First-of-Its-Kind TriClip™ System to Treat People With a Leaky Tricuspid Heart Valve

Panel of independent experts reviewed data from the TRILUMINATE™ pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system An investigational device in the U.S., TriClip is approved in more than 50 countries and has treated more than 10,000 people with tricuspid regurgitation worldwide ABBOTT PARK, Ill., Feb. 13, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the Circulatory System Devices Panel... Read more


ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep...

Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapy Part of Air11 Solutions, key features include Care Check-in, Personal Therapy Assistant, among others to provide support to patients and insights to clinicians and providers when used with AirView and myAir app SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) launched today its AirCurve 11 series devices, the company’s newest... Read more


Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023

Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis) Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency basis) Shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for fiscal year 2023 GAAP diluted loss per share of $(1.11) for Q4 2023, compared to GAAP diluted loss per share of $(0.89) for Q4 2022 Non-GAAP diluted earnings per share of $0.14 for both Q4 2023... Read more


Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results

SAN DIEGO / Feb 08, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis and 26% on an organic1 basis. U.S. revenue growth of 27% and international revenue growth of 27% on a reported basis. International revenue growth was 23% on... Read more


Baxter Reports Fourth-Quarter and Full-Year 2023 Results

Fourth-quarter sales from continuing operations of $3.89 billion increased 4% on a reported basis and 3% on a constant currency basis1 Fourth-quarter U.S. GAAP diluted earnings per share (EPS) from continuing operations of $0.14 and adjusted diluted EPS from continuing operations of $0.88 Full-year sales from continuing operations of $14.81 billion increased 2% on a reported basis and 3% on a constant currency basis Full-year U.S. GAAP diluted EPS (loss) from continuing... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB